Repligen (RGEN) PT Raised to $210 at HSBC
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $168.53 +0.55%
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Rating Summary:
23 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 26 | Down: 25 | New: 65
Join SI Premium – FREE
HSBC analyst Shubhangi Gupta raised the price target on Repligen (NASDAQ: RGEN) to $210.00 (from $170.00) while maintaining a Buy rating.
You May Also Be Interested In
- Canaan Inc. (CAN) PT Lowered to $2 at BTIG
- Tarsus Pharmaceuticals (TARS) PT Raised to $105 at Jefferies
- Pharvaris B.V. (PHVS) PT Raised to $75 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
